1900 related articles for article (PubMed ID: 29091343)
1. Metabolic memory: Evolving concepts.
Misra A; Bloomgarden Z
J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
[TBL] [Abstract][Full Text] [Related]
2. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
3. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.
; Orchard TJ; Nathan DM; Zinman B; Cleary P; Brillon D; Backlund JY; Lachin JM
JAMA; 2015 Jan; 313(1):45-53. PubMed ID: 25562265
[TBL] [Abstract][Full Text] [Related]
4. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
Abraira C; Duckworth W; McCarren M; Emanuele N; Arca D; Reda D; Henderson W;
J Diabetes Complications; 2003; 17(6):314-22. PubMed ID: 14583175
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
Diabetes Care; 1999 Jan; 22(1):99-111. PubMed ID: 10333910
[TBL] [Abstract][Full Text] [Related]
6. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S; Arima H; Gerstein HC; Holman RR; Woodward M; Reaven P; Hayward RA; Craven T; Coleman RL; Chalmers J;
Lancet Diabetes Endocrinol; 2017 Jun; 5(6):431-437. PubMed ID: 28365411
[TBL] [Abstract][Full Text] [Related]
7. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
8. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.
Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962
[TBL] [Abstract][Full Text] [Related]
9. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
Genuth S
Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
[TBL] [Abstract][Full Text] [Related]
10. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
11. Importance of controlling diabetes early--the concept of metabolic memory, legacy effect and the case for early insulinisation.
Ranjit Unnikrishnan I; Anjana RM; Mohan V
J Assoc Physicians India; 2011 Apr; 59 Suppl():8-12. PubMed ID: 21818992
[TBL] [Abstract][Full Text] [Related]
12. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
Diabetes; 1995 Nov; 44(11):1249-58. PubMed ID: 7589820
[TBL] [Abstract][Full Text] [Related]
13. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes.
Pantalone KM; Misra-Hebert AD; Hobbs TM; Wells BJ; Kong SX; Chagin K; Dey T; Milinovich A; Weng W; Bauman JM; Burguera B; Zimmerman RS; Kattan MW
J Diabetes; 2018 Mar; 10(3):192-199. PubMed ID: 28976724
[TBL] [Abstract][Full Text] [Related]
14. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
15. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
[TBL] [Abstract][Full Text] [Related]
16. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus.
Sousa GR; Pober D; Galderisi A; Lv H; Yu L; Pereira AC; Doria A; Kosiborod M; Lipes MA
Circulation; 2019 Feb; 139(6):730-743. PubMed ID: 30586738
[TBL] [Abstract][Full Text] [Related]
17. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
19. Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC).
Lachin JM; Nathan DM;
Diabetes Care; 2021 Sep; 44(10):2216-24. PubMed ID: 34548284
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
